None listed
Conditions
Brief summary
Expanded access use of INCB054329 to treat a single patient with metastatic renal cell carcinoma.
Interventions
DRUGINCB054329
Sponsors
Incyte Corporation
Eligibility
Inclusion criteria
\-
Exclusion criteria
\-
Outcome results
None listed